{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:18:37Z","timestamp":1767849517906,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.03.021","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T07:51:54Z","timestamp":1681717914000},"page":"38-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor\/Tezacaftor\/Ivacaftor"],"prefix":"10.1016","volume":"23","author":[{"given":"Caoimhe","family":"McParland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1592-134X","authenticated-orcid":false,"given":"Matthew","family":"Nunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore K.","family":"Marras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-9720","authenticated-orcid":false,"given":"Meredith","family":"Chiasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.03.021_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.659997","article-title":"Mycobacterium abscessus complex: a review of recent developments in an emerging pathogen","volume":"11","author":"Victoria","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"23","key":"10.1016\/j.jcf.2023.03.021_bib0002","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.3390\/ijms20235868","article-title":"Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients","volume":"20","author":"Degiacomi","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2023.03.021_bib0003","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71 Suppl 1","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.021_bib0004","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cells11071243","article-title":"CFTR modulator therapies: potential impact on airway infections in cystic fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.jcf.2023.03.021_bib0005","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3390\/ijms23073513","article-title":"The effect of CFTR modulators on airway infection in cystic fibrosis","volume":"23","author":"Harvey","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:12:44Z","timestamp":1767240764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323000954"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.021","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor\/Tezacaftor\/Ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}